aortic valve stenosis, chronic kidney disease
Conditions
Interventions
After qualification, the subjects are assigned 1: 1 ratio to the furosemide continuation group or tolvaptan administration group. Furosemide continuation group will continue the preoperative dose.
For
Sponsors
Tokyo Women's Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who satisfy all the following criteria are targeted. 1 Patient who is visiting or hospitalized for department of cardiovascular surgery or cardiology at Tokyo Women's Medical University Hospital 2 Patients diagnosed as severe aortic valve stenosis and judged to require TAVI treatment 3 Patients with complication of chronic kidney disease witheGFR <45 mL / min / 1.73 m 2 at the time of qualification confirmation 4 Patients who routinely use loop diuretics before TAVI surgery
Exclusion criteria
Exclusion criteria: Patients who violate the following criteria are excluded from this study 1 Patients receiving hemodialysis therapy 2 patients already taking tolvaptan 3 Patients with difficult oral medication 4 Patients who do not feel dry mouth 5 Those whose serum sodium level measured within 24 hours before the start of the study drug exceeds 150 mEq / ml 6 In addition, patients whose research managers judged inappropriate as subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in renal function before and one month after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes before and one month after treatment of the following items 1 weight 2 blood pressure 3 urine volume, urine osmotic pressure 4 serum electrolyte 5 Serum osmotic pressure 6 nerve fluid factor 7 Presence or absence of atrial fibrillation 8 echocardiographic findings | — |
Countries
Japan
Contacts
Public ContactSatoru Domoto
Tokyo Women's Medical University Department of Cardiovascular Surgery
Outcome results
None listed